Even as it completes an expansion in North Carolina, United Therapeutics is picking up for future use three buildings and a large parcel of land left idle by GlaxoSmithKline.
"We haven't finalized our plans for the properties acquired from GSK," Andrew Fisher, chief strategy officer and deputy general counsel, says in an email to FiercePharmaManufacturing.